Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Heart Failure ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Haemodynamic definitions and updated clinical classification of pulmonary hypertension.Eur Respir J. 2019; 53https://doi.org/10.1183/13993003.01913-2018
- Pulmonary arterial hypertension in schistosomiasis.Curr Opin Pulm Med. 2016; 22: 408-414
- Human schistosomiasis.Lancet. 2006; 368: 1106-1118
- Human schistosomiasis.Lancet. 2014; 383: 2253-2264
- Cardiopulmonary Manifestations of Hepatosplenic Schistosomiasis.Circulation. 2009; 119: 1518-1523
- A review of the literature on the use of ultrasonography in schistosomiasis with special reference to its use in field studies. 2. Schistosoma mansoni.Acta Trop. 1992; 51: 15-28
- Schistosomiasis Pulmonary Arterial Hypertension.Front Immunol. 2020; 11: 608883
- Pulmonary artery enlargement in schistosomiasis associated pulmonary arterial hypertension.BMC Pulm Med. 2015; 15: 118
- Immunopathological aspects of schistosomiasis-associated pulmonary arterial hypertension.J Infect. 2014; 68: 90-98
- Survival in schistosomiasis-associated pulmonary arterial hypertension.J Am Coll Cardiol. 2010; 56: 715-720
- The role of target therapies in schistosomiasis-associated pulmonary arterial hypertension.Chest Apr. 2012; 141: 923-928
- Survival of patients with schistosomiasis-associated pulmonary arterial hypertension in the modern management era.Eur Respir J. 2018; 51https://doi.org/10.1183/13993003.00307-2018
- Update on the Treatment of Pulmonary Arterial Hypertension.Arq Bras Cardiol. 2021; 117 (Atualizacao no Tratamento da Hipertensao Arterial Pulmonar): 750-764
- Sarcoidosis in America. Analysis Based on Health Care Use.Ann Am Thorac Soc. 2016; 13: 1244-1252
- Diagnosis and Treatment of Pulmonary Sarcoidosis: A Review.JAMA. 1 2022; 327: 856-867
- Predictors of Mortality in Pulmonary Sarcoidosis.Chest. 2018; 153: 105-113
- Predictors of mortality in fibrosing pulmonary sarcoidosis. Respiratory medicine.Aug. 2020; 169: 105997https://doi.org/10.1016/j.rmed.2020.105997
- Clinical predictors of pulmonary hypertension in sarcoidosis.Eur Respir J Aug. 2008; 32: 296-302
- Physiological predictors of survival in patients with sarcoidosis-associated pulmonary hypertension: results from an international registry.Eur Respir J. 2020; 55https://doi.org/10.1183/13993003.01747-2019
- Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics.Eur Respir J. 2005; 25: 783-788
- Prevalence of pulmonary hypertension in pulmonary sarcoidosis: the first large European prospective study.Eur Respir J. 2019; 54https://doi.org/10.1183/13993003.00897-2019
- Pulmonary arterial hypertension in patients with sarcoidosis: the Pulsar single center experience.Adv Exp Med Biol. 2013; 755: 299-305
- An update on sarcoidosis-associated pulmonary hypertension.Curr Opin Pulm Med. 2020; 26: 582-590
- Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis.Thorax. 2006; 61: 68-74
- Clinical features of sarcoidosis associated pulmonary hypertension: Results of a multi-national registry.Respir Med. 2018; 139: 72-78
- The frequency of diastolic dysfunction in patients with sarcoidosis and it's relationship with HLA DRB1∗ alleles.Sarcoidosis Vasculitis Diffuse Lung Dis. 2019; 36: 285-293
- Association of Sarcoidosis With Increased Risk of VTE: A Population-Based Study, 1976 to 2013.Chest. 2017; 151: 425-430
- WASOG statement on the diagnosis and management of sarcoidosis-associated pulmonary hypertension.Eur Respir Rev. 2022; : 31https://doi.org/10.1183/16000617.0165-2021
- Clinical Presentation and Treatment of High-Risk Sarcoidosis.Ann Am Thorac Soc. 2021; 18: 1935-1947
- Treatment of sarcoidosis-associated pulmonary hypertension: A single centre retrospective experience using targeted therapies.Sarcoidosis Vasculitis Diffuse Lung Dis. 2014; 31: 82-90
- Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension.Eur Respir J. 2017; 50https://doi.org/10.1183/13993003.00465-2017
- Riociguat for Sarcoidosis-Associated Pulmonary Hypertension: Results of a 1-Year Double-Blind, Placebo-Controlled Trial.Chest. 2022; 161: 448-457
- Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease.N Engl J Med. 2021; 384: 325-334
- Understanding the Similarities and Differences between Hepatic and Pulmonary Veno-Occlusive Disease.Am J Pathol. 2019; 189: 1159-1175
- Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology.Medicine (Baltimore). 2008; 87: 220-233
- Occupational exposure to organic solvents: a risk factor for pulmonary veno-occlusive disease.Eur Respir J. 2015; 46: 1721-1731
- Mechanisms of exertional dyspnoea in pulmonary veno-occlusive disease with EIF2AK4 mutations.Eur Respir J. 2014; 44: 1069-1072
- Pulmonary capillary haemangiomatosis: a distinct entity?.Eur Respir Rev : official J Eur Respir Soc. 2020; : 29https://doi.org/10.1183/16000617.0168-2019
- Use of vasodilators for the treatment of pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis: A systematic review.Respir Investig. 2019; 57: 183-190
- Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study.Lancet Respir Med. 2017; 5: 125-134
- Histiocytosis.Lancet. 2021; 398: 157-170
- Update on Pulmonary Langerhans Cell Histiocytosis.Front Med (Lausanne). 2020; 7: 582581
- Mechanisms of Exercise Limitation and Prevalence of Pulmonary Hypertension in Pulmonary Langerhans Cell Histiocytosis.Chest. 2020; 158: 2440-2448
- Lung transplantation for pulmonary langerhans' cell histiocytosis: a multicenter analysis.Transplantation. 2006; 81: 746-750
- Severe pulmonary hypertension in histiocytosis X.Am J Respir Crit Care Med. 2000; 161: 216-223
- Pulmonary Langerhans cell histiocytosis-associated pulmonary hypertension: clinical characteristics and impact of pulmonary arterial hypertension therapies.Chest. 2012; 142: 1150-1157
- Sickle Cell Disease: A Review.JAMA. 2022; 328: 57-68
- Global burden of sickle cell anaemia in children under five, 2010-2050: modelling based on demographics, excess mortality, and interventions.Plos Med. 2013; 10: e1001484
- Chronic Pulmonary Complications of Sickle Cell Disease.Chest. 2016; 149: 1313-1324
- Pulmonary Hypertension: Definition, Classification, and Diagnosis.Semin Respir Crit Care Med. 2017; 38: 561-570
- A hemodynamic study of pulmonary hypertension in sickle cell disease.N Engl J Med. 2011; 365: 44-53
- Pulmonary hypertension diagnosed by right heart catheterisation in sickle cell disease.Eur Respir J. 2012; 39: 112-118
- Mortality in adults with sickle cell disease and pulmonary hypertension.JAMA. 2012; 307: 1254-1256
- Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.N Engl J Med. 2004; 350: 886-895
- Clinical relevance of pulmonary vasculature involvement in sickle cell disease.Br J Haematol. 2019; 185: 317-326
- Morphologic and immunohistochemical features of pulmonary vasculopathy in end-stage left ventricular systolic failure.J Heart Lung Transplant. 2018; 37: 422-425
- Sickle cell disease: at the crossroads of pulmonary hypertension and diastolic heart failure.Heart. 2020; 106: 562-568
- An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease.Am J Respir Crit Care Med. 2014; 189: 727-740
- Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity.Blood. 2011; 118: 855-864
- Long-term tolerability of phosphodiesterase-5 inhibitors in pulmonary hypertension of sickle cell disease.Eur J Haematol. 2021; 107: 54-62
- Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies.Br J Haematol. 2010; 149: 426-435
Article info
Footnotes
None of the authors has any conflict of interest related to the content of this article.
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
